Medigene AG (MDG1.DE)
EUR 0.13
(-27.64%)
EUR 0.13
(-27.64%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 2.95 Million EUR | -20.83% |
| 2022 | 3.72 Million EUR | -7.41% |
| 2021 | 4.02 Million EUR | -21.92% |
| 2020 | 5.15 Million EUR | 2.08% |
| 2019 | 5.04 Million EUR | 233.93% |
| 2018 | 1.51 Million EUR | -55.69% |
| 2017 | 3.41 Million EUR | 67.01% |
| 2016 | 2.04 Million EUR | 174.6% |
| 2015 | 744 Thousand EUR | -92.98% |
| 2014 | 10.59 Million EUR | 2.33% |
| 2013 | 10.35 Million EUR | 0.0% |
| 2012 | - EUR | 0.0% |
| 2011 | - EUR | 0.0% |
| 2010 | - EUR | 0.0% |
| 2009 | - EUR | 0.0% |
| 2008 | - EUR | 0.0% |
| 2007 | - EUR | 0.0% |
| 2006 | - EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 2.54 Million EUR | 0.0% |
| 2024 Q1 | - EUR | -100.0% |
| 2023 Q2 | 3.39 Million EUR | 0.0% |
| 2023 Q4 | 2.03 Million EUR | 0.0% |
| 2023 Q3 | 2.03 Million EUR | -39.96% |
| 2023 FY | 2.95 Million EUR | -20.83% |
| 2023 Q1 | - EUR | -100.0% |
| 2022 Q1 | - EUR | -100.0% |
| 2022 Q4 | 2.74 Million EUR | 0.0% |
| 2022 Q2 | 3.48 Million EUR | 0.0% |
| 2022 FY | 3.72 Million EUR | -7.41% |
| 2022 Q3 | 2.74 Million EUR | -21.21% |
| 2021 Q4 | 4.02 Million EUR | 28.32% |
| 2021 Q3 | 3.13 Million EUR | -24.16% |
| 2021 Q1 | - EUR | -100.0% |
| 2021 Q2 | 4.13 Million EUR | 0.0% |
| 2021 FY | 4.02 Million EUR | -21.92% |
| 2020 Q1 | - EUR | -100.0% |
| 2020 Q4 | 5.15 Million EUR | 29.11% |
| 2020 Q2 | 4.91 Million EUR | 0.0% |
| 2020 FY | 5.15 Million EUR | 2.08% |
| 2020 Q3 | 3.99 Million EUR | -18.83% |
| 2019 Q2 | 5.52 Million EUR | -4.03% |
| 2019 FY | 5.04 Million EUR | 233.93% |
| 2019 Q4 | 5.04 Million EUR | -20.82% |
| 2019 Q3 | 6.37 Million EUR | 15.5% |
| 2019 Q1 | 5.75 Million EUR | 280.49% |
| 2018 FY | 1.51 Million EUR | -55.69% |
| 2018 Q4 | 1.51 Million EUR | 5.96% |
| 2018 Q1 | 1.57 Million EUR | -53.81% |
| 2018 Q2 | 1.51 Million EUR | -3.81% |
| 2018 Q3 | 1.42 Million EUR | -5.87% |
| 2017 Q3 | 1.21 Million EUR | -9.01% |
| 2017 Q1 | 497 Thousand EUR | -75.67% |
| 2017 FY | 3.41 Million EUR | 67.01% |
| 2017 Q4 | 3.41 Million EUR | 181.52% |
| 2017 Q2 | 1.33 Million EUR | 168.01% |
| 2016 Q4 | 2.04 Million EUR | 241.64% |
| 2016 FY | 2.04 Million EUR | 174.6% |
| 2016 Q3 | 598 Thousand EUR | -7.57% |
| 2016 Q2 | 647 Thousand EUR | -7.04% |
| 2016 Q1 | 696 Thousand EUR | -6.45% |
| 2015 Q1 | - EUR | 0.0% |
| 2015 Q2 | 837 Thousand EUR | 0.0% |
| 2015 FY | 744 Thousand EUR | -92.98% |
| 2015 Q4 | 744 Thousand EUR | -5.82% |
| 2015 Q3 | 790 Thousand EUR | -5.62% |
| 2014 Q4 | - EUR | 0.0% |
| 2014 Q2 | - EUR | 0.0% |
| 2014 FY | 10.59 Million EUR | 2.33% |
| 2014 Q1 | - EUR | 0.0% |
| 2014 Q3 | - EUR | 0.0% |
| 2013 Q1 | - EUR | 0.0% |
| 2013 FY | 10.35 Million EUR | 0.0% |
| 2013 Q3 | - EUR | 0.0% |
| 2013 Q2 | - EUR | 0.0% |
| 2013 Q4 | - EUR | 0.0% |
| 2012 Q3 | - EUR | 0.0% |
| 2012 Q1 | - EUR | 0.0% |
| 2012 FY | - EUR | 0.0% |
| 2012 Q4 | - EUR | 0.0% |
| 2012 Q2 | - EUR | 0.0% |
| 2011 FY | - EUR | 0.0% |
| 2011 Q1 | - EUR | 0.0% |
| 2011 Q2 | - EUR | 0.0% |
| 2011 Q3 | - EUR | 0.0% |
| 2011 Q4 | - EUR | 0.0% |
| 2010 FY | - EUR | 0.0% |
| 2010 Q4 | - EUR | 0.0% |
| 2010 Q3 | - EUR | 0.0% |
| 2010 Q2 | - EUR | 0.0% |
| 2010 Q1 | - EUR | 0.0% |
| 2009 FY | - EUR | 0.0% |
| 2009 Q4 | - EUR | 0.0% |
| 2008 FY | - EUR | 0.0% |
| 2007 FY | - EUR | 0.0% |
| 2006 FY | - EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| BioNTech SE | 219.1 Million EUR | 98.654% |
| CureVac N.V. | 41.85 Million EUR | 92.952% |
| Biotest Aktiengesellschaft | 689.8 Million EUR | 99.572% |
| Biotest Aktiengesellschaft | 689.8 Million EUR | 99.572% |
| BRAIN Biotech AG | 4.65 Million EUR | 36.682% |
| Formycon AG | 29.48 Million EUR | 89.995% |
| Heidelberg Pharma AG | 5.83 Million EUR | 49.412% |